Abstract
Objective To evaluate the synergistic effects created by fine particulate matter (PM2.5) and corticosteroid use on hospitalization and mortality in older adults at high-risk for cardiovascular thromboembolic events (CTEs).
Design and Setting A retrospective cohort study using a US nationwide administrative healthcare claims database.
Participants A 50% random sample of participants with high-risk conditions for CTE from the 2008-2016 Medicare Fee-for-Service population.
Exposures Corticosteroid therapy and seasonal-average PM2.5.
Main Outcome Measures Incidences of myocardial infarction or acute coronary syndrome, ischemic stroke or transient ischemic attack, heart failure, venous thromboembolism, atrial fibrillation, and all-cause mortality. We assessed additive interactions between PM2.5 and corticosteroids using estimates of the relative excess risk due to interaction (RERI) obtained using marginal structural models for causal inference.
Results Among the 1,936,786 individuals in the high CTE risk cohort (mean age 76.8, 40.0% male, 87.4% White), the mean PM2.5 exposure level was 8.3 ± 2.4 μg/m3 and 37.7% had at least one prescription for a systemic corticosteroid during follow-up. For all outcomes, we observed increases in risk associated with corticosteroid use and with increasing PM2.5 exposure. PM2.5 demonstrated a non-linear relationship with some outcomes. We also observed evidence of an interaction existing between corticosteroid use and PM2.5 for some CTEs. For an increase in PM2.5 from 8 μg/m3 to 12 μg/m3 (a policy-relevant change), the RERI of corticosteroid use and PM2.5 was significant for heart failure (15.6%, 95% CI: 4.0%-27.3%). Increasing PM2.5 from 5 μg/m3 to 10 μg/m3 yielded significant RERIs for incidences of heart failure (32.4; 95% CI: 14.9%-49.9%) and myocardial infarction/acute coronary syndromes (29.8%; 95% CI: 5.5%-54.0%).
Conclusion PM2.5 and systemic corticosteroid use were independently associated with increases in CTE hospitalizations. We also found evidence of significant additive interactions between the two exposures for heart failure and myocardial infarction/acute coronary syndromes suggesting synergy between these two exposures.
Strengths and Limitations of this Study
We conduct analyses using robust causal inference and machine learning techniques and incorporate a large set of individual-level factors that are typically absent in environmental health analyses with large claims data sets.
We present statistics that evaluate the synergy between fine particulate matter and corticosteroid therapy on the additive scale, which is more relevant for assessing excess risks and informing policy.
Patient medical history prior to receiving Medicare benefits is unknowable within a Fee-for-Service claims database, which may lead to exclusion of some high-risk individuals from the cohort.
We censor participants after the earlier of the end of first corticosteroid regimen or the first incidence of the outcome of interest, which makes the analyses statistically tractable but sacrifices some information in the data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by National Institutes of Health grants R01AG060232, 1K01ES032458, and 5T32ES007142.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Rutgers Institutional Review Board (ID Pro20170001685).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Some of the values in Table 1 were incorrect. During the last resubmission, we were required to provide both a marked and clean copy of our manuscript. We tried to upload the clean copy in version 2, but some artifacts from Microsoft Word's track changes feature persisted.
Data Availability
For data privacy reasons, the Medicare data used in this study cannot be made publicly available, but interested parties can request access by applying through the US Centers for Medicare and Medicaid Services. The PM2.5 exposure data are publicly available at the following link: https://doi.org/10.7927/0rvr-4538. Area-level covariates used herein are also publicly available from the US Census Bureau website. Code for fitting the models and for plotting estimates found within this manuscript is available at: https://github.com/kevjosey/pm-steroid.
